Abstracts tagged "Pediatric rheumatology"

Abstract Number: 133 • 2020 Pediatric Rheumatology Symposium
Pediatric Rheumatology Consultation for Both Traditional and Emerging Rheumatic Diseases in the Critical Care Setting
Jennifer Rammel¹, Kristen Staggers ², Satid Thammasitboon ², Jorge Coss Bu ², Amanda Brown ³ and Eyal Muscal ⁴, ¹Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ²Baylor College of Medicine, Houston, Texas, ³Baylor College of Medicine, Houston, ⁴Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston
Background/Purpose: In addition to traditional rheumatic diseases (TRDs), Pediatric Rheumatologists are often consulted on emerging rheumatic diseases (ERDs) such as autoimmune encephalitis, seronegative vasculitides, and…
Abstract Number: 059 • 2020 Pediatric Rheumatology Symposium
Challenges Faced by Families of Children with an Auto-inflammatory Disease
Lori Tucker¹, Maria Belen ², Jenny Tekano ², Iwona Niemietz ³, Martina Sundqvist ³ and Kelly Brown ³, ¹BC Children's Hospital, Vancouver, British Columbia, Canada, ²BC CHildren's Hospital, Vancouver, Canada, ³BC Children's Hospital Research Institute, Vancouver, Canada
Background/Purpose: Auto-inflammatory diseases (AIDs) are rare disorders that usually present in young children. Disease episodes, characterized by recurrent inflammation, are often frequent and unpredictable, and…
Abstract Number: 169 • 2020 Pediatric Rheumatology Symposium
Addressing the Pediatric Rheumatology Workforce Shortage: Is Early Exposure Enough?
Katherine Schultz¹, Theresa Hennard ², Britne Gregg ³, Melissa Klein ⁴, Francis Real ² and Jennifer Huggins ², ¹Cincinnati Childrens Hospital Medical Center, Newport, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³, ⁴Cincinnati
Background/Purpose: The current demand for pediatric rheumatologists in the United States exceeds supply by 33%, a figure projected to worsen to 61% by 20301. This…
Abstract Number: 063 • 2020 Pediatric Rheumatology Symposium
Musculoskeletal Ultrasound Assessment in Pediatric Knee Hypermobility
Laura Ballenger¹, Ann Salvator ² and Edward Oberle ¹, ¹Division of Rheumatology, Nationwide Children's Hospital, Columbus, ²Biostatistics Resource at Nationwide Children's Hospital, Columbus
Background/Purpose: While musculoskeletal ultrasound (MSUS) use in pediatric rheumatology is becoming more common, the majority of pediatric MSUS literature continues to focus on ultrasound findings…
Abstract Number: 172 • 2020 Pediatric Rheumatology Symposium
Improved Self-efficacy and Knowledge in Pediatric Rheumatology Among General Pediatric Residents Following the Introduction of a Standardized Teaching Series
Elizaveta Limenis¹, Alhanouf Alsaleem ², Herman Tam ³, Piya Lahiry ¹, Kate Neufeld ⁴ and Shirley Tse ⁵, ¹Hospital for Sick Children, Toronto, Canada, ²KFSH&RC, RiYADH, Saudi Arabia, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of Toronto, The Hospital for Sick Children, Toronto, Canada, ⁵SickKids, Toronto, Canada
Background/Purpose: Self-efficacy and knowledge in core pediatric rheumatology (PR) topics are generally low among pediatric residents before their mandatory rotations in PR. The teaching style…
Abstract Number: 005 • 2020 Pediatric Rheumatology Symposium
Single Cell Sequencing of the Skin to Define Cell Populations of Interest in Localized Scleroderma (LS)
Emily Mirizio ¹, Wei Chen ², Tao Sun ², Tracy Tabib ³, Kaila Schollaert-Fitch ¹, Robert Lafyatis ⁴, Heidi Jacobe ⁵ and Kathryn Torok¹, ¹Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ²Research Computing Core at Children's Hospital of Pittsburgh, Pittsburgh, ³Univ of Pittsburgh Med Ctr, Pittsburgh, ⁴Univ of Pittsburgh Med Ctr, Pittsburgh, Pittsburgh, ⁵University of Texas Southwestern Medical Ctr, Dallas
Background/Purpose: Scleroderma is an autoimmune disorder involving inflammatory driven fibrosis, which encompasses systemic sclerosis (SSc) and localized scleroderma (LS). LS and SSc share histological characteristics,…
Abstract Number: 064 • 2020 Pediatric Rheumatology Symposium
The First 18 Months of a Pediatric Rheumatology Service at a Tertiary Referral Hospital in Kenya
Angela Migowa¹ and James Orwa ², ¹Aga Khan University Hospital, Montreal, Kenya, ²AGA KHAN UNIVERSITY HOSPITAL, Nairobi, Kenya
Background/Purpose: Pediatric rheumatic diseases impart a significant disease burden upon children and their families with the potential to cause diminished quality of life and significant…
Abstract Number: 174 • 2020 Pediatric Rheumatology Symposium
Improving Hospital Discharge Instructions for Pediatric Rheumatology Patients
Laura Ballenger¹, Vidya Sivaraman ², Stephanie Lemle ³ and Kyla Driest ¹, ¹Division of Rheumatology, Nationwide Children's Hospital, Columbus, ²Division of Rheumatology, Nationwide Children's Hospital, Bexley, ³Quality Improvement Services, Nationwide Children's Hospital, Columbus
Background/Purpose: Communication, including clear discharge instructions, is a crucial aspect of the hospital discharge process. Development of standardized discharge templates has been reported to improve…
Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium
Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases
Mei-Sing Ong¹, Deborah Rothman ² and Marc Natter ³, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, ²Massachusetts General Hospital, Springfield, ³Boston Children's Hospital, Boston
Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium
Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus
Linda Wagner-Weiner ¹, Vidya Sivaraman ², Karen James ³, Eric Yen ⁴, Kathleen O'Neil ⁵, Dana Gerstbacher ⁶, Ann Marie Szymanski⁷, Kimberly Morishita ⁸ and David Cabral ⁹ for the CARRA investigators, ¹University of Chicago, Chicago, Illinois, ²Division of Rheumatology, Nationwide Children's Hospital, Bexley, ³University of Utah, 84113, Utah, ⁴UCLA, Los Angeles, California, ⁵University of Indiana School of Medicine, Indianapolis, Indiana, ⁶Stanford University School of Medicine, Palo Alto, California, ⁷Tampa, Florida, ⁸University of British Columbia - Vancouver, Vancouver, British Columbia, Canada, ⁹BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…
Abstract Number: 192 • 2020 Pediatric Rheumatology Symposium
Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease
Stephen Wong¹, Amy Gaultney ² and Deborah McCurdy ³, ¹University of California Los Angeles, Los Angeles, California, ²UCLA, Los Angeles, California, ³UCLA Medical Center, Los Angeles, California
Background/Purpose: Many children with rheumatic diseases require immunosuppressive treatments, however these medications put them at risk for contracting opportunistic infections leading to severe morbidity and…
Abstract Number: 012 • 2020 Pediatric Rheumatology Symposium
Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases
Jacqueline Madison¹ and Jason Knight ¹, ¹University of Michigan, Ann Arbor
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…
Abstract Number: 069 • 2020 Pediatric Rheumatology Symposium
Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up
Liora Harel ¹, Gil Amarilyo ² and mohammad hammad saied³, ¹Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ²Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, ³Schneider Medical Center, Kaboul village 24963, Israel
Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…
Abstract Number: 013 • 2020 Pediatric Rheumatology Symposium
A Preliminary Data-driven Anatomic Classification for Childhood Takayasu Arteritis (cTA)
Ellen Go¹, Simon Eng ², David Cabral ³ and Rae Yeung ¹, ¹The Hospital for Sick Children, Toronto, Canada, ²Toronto, Canada, ³BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Background/Purpose: The pattern of arterial involvement and disease severity varies in those affected with cTA. Distinct imaging patterns that have some congruence with clinical phenotype…
Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium
Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus
Lauren Ambler¹, Rula Issa ², Stephanie Pan ² and Rebecca Trachtman ², ¹Mount Sinai Hospital, New York, ²Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].